For the quarter ended June 2025, TransMedics (TMDX) reported revenue of $157.37 million, up 37.7% over the same period last year. EPS came in at $0.92, compared to $0.35 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $147.37 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +91.67%, with the consensus EPS estimate being $0.48.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- United States: $152.19 million compared to the $142.05 million average estimate based on four analysts. The reported number represents a change of +40.3% year over year.
- Geographic Revenues- All other countries: $4.16 million versus $4.47 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.8% change.
- Net revenue by OCS product- OCS Lung net revenue: $4.15 million versus the four-analyst average estimate of $4.5 million. The reported number represents a year-over-year change of -11.5%.
- Net revenue by OCS product- OCS Liver net revenue: $115.86 million versus $108.56 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +50.4% change.
- Net revenue by OCS product- OCS Heart net revenue: $32.17 million versus $32.38 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.
View all Key Company Metrics for TransMedics here>>>
Shares of TransMedics have returned -19.4% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TransMedics Group, Inc. (TMDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
